AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 271 min read$BDX

Feld Michael sold $11K of BDX

Feld Michael (EVP, Chief Revenue Officer) sold 75 shares of BECTON DICKINSON & CO (BDX) at $152.80 on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Feld Michael
Published Jun 27, 2026, 12:47 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 27, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BDX
Neutral
high confidence
Mentioned
$BDX
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

The only new information is the reported open-market sale details (75 shares at $152.80) by EVP/Chief Revenue Officer Michael Feld under a 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment/positioning, but it does not introduce new fundamentals or guidance.

03

What to watch

The disclosure size is small and explicitly pre-arranged (10b5-1), which typically reduces interpretive weight versus unscheduled sales.

Relevance 2/10Novelty 3/10Timing: SEC EDGAR filing dated 2026-06-26 (filed 2026-06-26T20:47:39-04:00)

Background

The article is an SEC Form 4 insider transaction disclosure for Becton Dickinson & Co.

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

SEC Form 4 shows Becton Dickinson officer Michael Feld sold 75 shares at $152.80 under a 10b5-1 plan on 2026-06-26.

Expected impact

Low likelihood of a sustained price move from this disclosure alone.

Evidence & confidence

The filing is a small, pre-arranged open-market sale by an EVP; no new operational, financial, or regulatory facts are disclosed.

Market effects

Sector

None—this is company-specific insider transaction with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with private information, so some traders may briefly fade/hedge around the headline.

Key entities

  • public_company
    BDX

    Becton Dickinson & Co, issuer of the Form 4 insider transaction.

  • insider
    Michael Feld

    EVP, Chief Revenue Officer; reported an open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

raps.org7 min
AUG 6
$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

rttnews.com2 min
AUG 6
$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.

prnewswire.com6 min